Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma
Open Access
- 10 August 2020
- journal article
- research article
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2020, 1-10
Abstract
Aims. To evaluate the expression of DSG1 and DSG2 and investigate their clinicopathological significance in EHCC. Method. The protein expression of DSG1 and DSG2 was measured by EnVision immunohistochemistry in 15 normal biliary tract tissues, 10 biliary tract adenoma tissues, 30 peritumoral tissues, and 100 EHCC tumour tissues. Result. The expression of the DSG1 and DSG2 proteins was significantly lower in EHCC tumour tissues than in normal biliary tract tissues, biliary tract adenoma, and peritumoral tissues (). Adenoma and peritumoral tissues with negative DSG1 and/or DSG2 protein expression exhibited atypical hyperplasia. DSG1 expression was positively correlated with DSG2 expression in EHCC (). In patients with good differentiation, no invasion, no lymph metastasis, TNM I + II stage, and radical surgery, the positive expression of DSG1 and DSG2 proteins was higher (). In comparison to patients with negative DSG1 and/or DSG2 expression, the average overall survival time of those with positive expression was significantly longer (). Cox multivariate analysis revealed that negative DSG1 and DSG2 expressions were independent of poor prognosis factors in EHCC patients. The AUC calculated for DSG1 was 0.681 (95% confidence interval: 0.594–0.768) and that for DSG2 was 0.645 (95% confidence interval: 0.555–0.734), while that for DSG1 and DSG2 was 0.772 (95% confidence interval: 0.609-0.936). Conclusions. Negative protein expression of DSG1 and DSG2 is closely related to the pathogenesis, severe clinicopathological characteristics, aggressive biological behaviours, and dismal prognosis in EHCC.
Keywords
Funding Information
- National Natural Science Foundation of China (81472738)
This publication has 19 references indexed in Scilit:
- Cholangiocarcinoma: a guide for the nonspecialistInternational Journal of General Medicine, 2018
- Evaluation and management of intrahepatic and extrahepatic cholangiocarcinomaCancer, 2016
- Expression of desmogleins 1–3 and their clinical impacts on human lung cancerPathology - Research and Practice, 2015
- Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate CancerPLOS ONE, 2014
- CholangiocarcinomaThe Lancet, 2014
- Aberrant expression and altered cellular localization of desmosomal and hemidesmosomal proteins are associated with aggressive clinicopathological features of oral squamous cell carcinomaVirchows Archiv, 2014
- Heterogeneous and abnormal localization of desmosomal proteins in oral intraepithelial neoplasmsJournal of Oral Science, 2014
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: an updateGut, 2012
- Kallikrein-5 Promotes Cleavage of Desmoglein-1 and Loss of Cell-Cell Cohesion in Oral Squamous Cell CarcinomaJournal of Biological Chemistry, 2011
- Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patientsPathology, 2008